We have shown that combined treatment with trastuzumab and lapatinib improves response to chemotherapy in SKBR3 breast cancer cells and decreases tumour growth in BT-474 xenografts [7], with the combination also showing improved response in the neoadjuvant treatment of HER2-positive breast cancer in some clinical trials [8–11]. This evidence concerns the gene ERBB2 and neoplasm.